Fractyl Health

Fractyl Health is pioneering treatments for T2D based on scientific insights of a potential root cause of metabolic diseases identified by its founders over a decade ago. They recognized that treating the symptoms of metabolic disease alone did not prevent the disease from worsening and that new therapeutic approaches were needed. Fractyl Health’s lead therapeutic candidate, the Revita DMR® System (Revita®), is designed as an outpatient endoscopic procedural therapy to target a potential root cause of T2D – the gut.

Revita has been developed based on research conducted by Fractyl Health and others indicating that an area of the small intestine, called the duodenum, plays a key role in the development of T2D. Diets high in fat and sugar cause thickening of the duodenal lining (the duodenal mucosa) over time. The Revita procedure is designed to ablate the dysfunctional mucosa in an outpatient procedure, enabling the regeneration of a new, healthy lining within a matter of days. Revita has already been studied in clinical studies involving close to 300 patients. It has received U.S. FDA Breakthrough Device Designation for investigational use as well as a CE mark in Europe.

Fractyl Health has the potential to address T2D and insulin resistance utilizing Revita. In an earlier stage of development, Rejuva®, a novel pancreatic gene therapy platform, could enable the long-term remission of T2D by addressing insulin insufficiency. Altogether, Fractyl Health’s vision is to offer the possibility of eradicating metabolic disease for the many who suffer from T2D and for society burdened by its explosive rise globally.